BOSTON--(BUSINESS WIRE)--Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, chief executive officer, will present the company’s target discovery and clinical development work during the 31st Annual Piper Jaffray Healthcare Conference taking place December 3-5, 2019 in New York, NY.
Date: Wednesday, December 4, 2019
Time: 9:10-9:30 a.m. ET
Location: New York, NY
The 31st Annual Piper Jaffray Healthcare Conference showcases senior management teams from leading public and private companies delivering presentations to an audience of institutional investors, equity portfolio managers and research analysts.
Cerevance is a private pharmaceutical company focused on central nervous system diseases. The company’s powerful NETSseq target discovery platform is being applied to a growing collection of more than 6,000 human brain tissue samples, yielding a pipeline of novel discovery-stage and clinical-stage compounds. With a proven track record, Cerevance’s team believes it is well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.